17D yellow fever vaccines: New insights. A report of a workshop held during the World Congress on Medicine and Health in the Tropics, Marseille, France, Monday 12 September 2005

Vaccine

Volumn 25, Issue 15, 2007, Pages 2758-2765

  Barrett, Alan D T ^a   Monath, Thomas P ^b   Barban, Veronique ^c   Niedrig, Matthias ^d   Teuwen, Dirk E ^c  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^b Acambis   (United States)

^c SANOFI PASTEUR   (France)

^d ROBERT KOCH INSTITUTE   (Germany)

Author keywords

Adverse events; Vaccines; Yellow fever

Indexed keywords

YELLOW FEVER VACCINE;

AFRICA; ANTIBODY TITER; ARTHRALGIA; CONFERENCE PAPER; DRUG EFFICACY; DRUG SAFETY; ENDEMIC DISEASE; FEVER; FRANCE; GENETIC STABILITY; HEADACHE; HEALTH HAZARD; HIGH RISK POPULATION; HUMAN; IMMUNOGENICITY; MYALGIA; POSTVACCINAL ENCEPHALITIS; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SOUTH AMERICA; TRAVEL; VACCINATION; VIRUS STRAIN; YELLOW FEVER;

DISEASE OUTBREAKS; ENDEMIC DISEASES; HUMANS; YELLOW FEVER; YELLOW FEVER VACCINE;

EID: 33947124138     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.12.015     Document Type: Conference Paper

References (45)

1. Monath T.P. Yellow fever vaccine. In: Plotkin S. (Ed). Vaccines. 4 ed. (2004), W B Saunders, Phildelphia 1095-1176
2. World Health Organization. Yellow fever vaccine. WHO position paper. Wkly Epidemiol Rec 78 40 (2003) 349-359
3. Wilson M.E., Chen L.H., and Barnett E.D. Yellow fever immunizations: indications and risks. Curr Infect Dis Rep 6 1 (2004) 34-42
4. World Health Organization. WHO vaccine-preventable diseases: monitoring system. 2005 global summary. Geneva: WHO; 2005.
5. Progress in the control of yellow fever in Africa. Wkly Epidemiol Rec 80 (2005) 50-55
6. Arguin P.M., Kozarsky P.E., and Navin A.W. Yellow fever. Traveller's health: yellow book (2005-2006), Health Information for International Travel
7. Vazquez S., Valdes O., Pupo M., Delgado I., Alvarez M., Pelegrino J., et al. MAC-ELISA and ELISA inhibition methods for detection of antibodies after yellow fever vaccination. J Virol Methods 110 2 (2003) 179-184
8. De Cock K.M., Monath T.P., Nasidi A., Tukei P.M., Enriquez J., Lichfield P., et al. Epidemic yellow fever in eastern Nigeria, 1986. Lancet 1 8586 (1988) 630-633
9. Nasidi A., Monath T.P., DeCock K., Tomori O., Cordellier R., Olaleye O.D., et al. Urban yellow fever epidemic in western Nigeria, 1987. Trans R Soc Trop Med Hyg 83 3 (1989) 401-406
10. Monath T.P., and Cetron M.S. Prevention of yellow fever in persons traveling to the tropics. Clin Infect Dis 34 10 (2002) 1369-1378
11. Monath T.P., Lee V.H., Wilson D.C., Fagbami A., and Tomori O. Arbovirus studies in Nupeko forest, a possible natural focus of yellow fever virus in Nigeria. I. Description of the area and serological survey of humans and other vertebrate hosts. Trans R Soc Trop Med Hyg 68 1 (1974) 30-38
12. Monath T. Epidemiology of yellow fever: current status and speculations on future trends. In: Saluzzo J.-F., and Dodet B. (Eds). Factors in the emergence of arbovirus diseases (1997), Elsevier, Paris 143-156
13. Monath T., Craven R., Adjukiewicz A., Germain M., Francy D., Ferrara L., et al. Yellow fever in the Gambia, 1978-1979: epidemiologic aspects with observations on the occurrence of orungo virus infections. Am J Trop Med Hyg 29 5 (1980) 912-928
14. Robertson S., Hull B., Tomori O., Bele O., LeDuc J., and Esteves K. Yellow fever: a decade of re-emergence. JAMA 276 (1996) 1157-1162
15. Barban V., Girerd Y., Aguirre M., Gulia S., Petiard F., Riou P., et al. High stability of yellow fever 17D-204 vaccine: a 12-year restrospective analysis of large-scale production. Vaccine 25 15 (2007) 2949-2958
16. Dupuy A., Despres P., Cahour A., Girard M., and Bouloy M. Nucleotide sequence comparison of the genome of two 17D-204 yellow fever vaccines. Nucleic Acids Res 17 10 (1989) 3989
17. Rice C.M., Lenches E.M., Eddy S.R., Shin S.J., Sheets R.L., and Strauss J.H. Nucleotide sequence of yellow fever virus: implications for flavivirus gene expression and evolution. Science 229 4715 (1985) 726-733
18. Belmusto-Worn V.E., Sanchez J.L., McCarthy K., Nichols R., Bautista C.T., Magill A.J., et al. Randomized, double-blind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (Arilvax and YF-VAX) in healthy infants and children in Peru. Am J Trop Med Hyg 72 2 (2005) 189-197
19. Camacho L.A., de Aguiar S.G., Freire Mda S., Leal Mda L., do Nascimento J.P., Iguchi T., et al. Reactogenicity of yellow fever vaccines in a randomized, placebo-controlled trial. Rev Saude Publica 39 3 (2005) 413-420
20. Camacho L.A., Freire Mda S., Leal Mda L., Aguiar S.G., Nascimento J.P., Iguchi T., et al. Immunogenicity of WHO-17D and Brazilian 17DD yellow fever vaccines: a randomized trial. Rev Saude Publica 38 5 (2004) 671-678
21. Monath T.P., Nichols R., Archambault W.T., Moore L., Marchesani R., Tian J., et al. Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial. Am J Trop Med Hyg 66 5 (2002) 533-541
22. Niedrig M., Lademann M., Emmerich P., and Lafrenz M. Assessment of IgG antibodies against yellow fever virus after vaccination with 17D by different assays: neutralization test, haemagglutination inhibition test, immunofluorescence assay and ELISA. Trop Med Int Health 4 12 (1999) 867-871
23. Reinhardt B., Jaspert R., Niedrig M., Kostner C., and L'Age-Stehr J. Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection. J Med Virol 56 2 (1998) 159-167
24. Xie H., Cass A.R., and Barrett A.D.T. Yellow fever 17D vaccine virus isolated from healthy vaccinees accumulates very few mutations. Virus Res 55 (1998) 93-99
25. Fever, jaundice, and multiple organ system failure associated with 17D-derived yellow fever vaccination 1996-2001. MMWR Morb Mortal Wkly Rep 50 30 (2001) 643-645
26. Chan R.C., Penney D.J., Little D., Carter I.W., Roberts J.A., and Rawlinson W.D. Hepatitis and death following vaccination with 17D-204 yellow fever vaccine. Lancet 358 9276 (2001) 121-122
27. Doblas A., Domingo C., Bae H.G., Bohorquez C.L., de Ory F., Niedrig M., et al. Yellow fever vaccine-associated viscerotropic disease and death in Spain. J Clin Virol 36 2 (2006) 156-158
28. Struchiner C.J., Luz P.M., Dourado I., Sato H.K., Aguiar S.G., Ribeiro J.G., et al. Risk of fatal adverse events associated with 17DD yellow fever vaccine. Epidemiol Infect 132 5 (2004) 939-946
29. Vasconcelos P.F., Luna E.J., Galler R., Silva L.J., Coimbra T.L., Barros V.L., et al. Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases. Lancet 358 9276 (2001) 91-97
30. Zhou Q., Liu D.W., Shi Y., Long Y., Li D.J., Liu H.Z., et al. Adverse effects of attenuated yellow fever vaccine with multiple organ injury-a case report. Zhonghua Yi Xue Za Zhi 85 13 (2005) 936
31. Martin M., Tsai T.F., Cropp B., Chang G.J., Holmes D.A., Tseng J., et al. Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases. Lancet 358 9276 (2001) 98-104
32. Cetron M.S., Marfin A.A., Julian K.G., Gubler D.J., Sharp D.J., Barwick R.S., et al. Yellow fever vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2002. MMWR Recomm Rep 51 RR-17 (2002) 1-11 [quiz CE1-4]
33. Fatal viral encephalitis following 17D yellow fever vaccine inoculation. Report of a case in a 3-year-old child. JAMA 198 6 (1966) 671-672
34. Kengsakul K., Sathirapongsasuti K., and Punyagupta S. Fatal myeloencephalitis following yellow fever vaccination in a case with HIV infection. J Med Assoc Thai 85 1 (2002) 131-134
35. Khromava A.Y., Eidex R.B., Weld L.H., Kohl K.S., Bradshaw R.D., Chen R.T., et al. Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events. Vaccine 23 25 (2005) 3256-3263
36. Lawrence G.L., Burgess M.A., and Kass R.B. Age-related risk of adverse events following yellow fever vaccination in Australia. Commun Dis Intell 28 2 (2004) 244-248
37. Barwick R. History of thymoma and yellow fever vaccination. Lancet 364 9438 (2004) 936
38. Engel A.R., Vasconcelos P.F., McArthur M.A., and Barrett A.D. Characterization of a viscerotropic yellow fever vaccine variant from a patient in Brazil. Vaccine 24 15 (2006) 2803-2809
39. Vasconcelos P.F., Bryant J.E., da Rosa T.P., Tesh R.B., Rodrigues S.G., and Barrett A.D. Genetic divergence and dispersal of yellow fever virus, Brazil. Emerg Infect Dis 10 9 (2004) 1578-1584
40. Jennings A.D., Gibson C.A., Miller B.R., Mathews J.H., Mitchell C.J., Roehrig J.T., et al. Analysis of a yellow fever virus isolated from a fatal case of vaccine-associated human encephalitis. J Infect Dis 169 3 (1994) 512-518
41. Galler R., Pugachev K.V., Santos C.L., Ocran S.W., Jabor A.V., Rodrigues S.G., et al. Phenotypic and molecular analyses of yellow fever 17DD vaccine viruses associated with serious adverse events in Brazil. Virology 290 2 (2001) 309-319
42. Tesh R.B., Guzman H., da Rosa A.P., Vasconcelos P.F., Dias L.B., Bunnell J.E., et al. Experimental yellow fever virus infection in the Golden Hamster (Mesocricetus auratus). I. Virologic, biochemical, and immunologic studies. J Infect Dis 183 10 (2001) 1431-1436
43. Xiao S.Y., Zhang H., Guzman H., and Tesh R.B. Experimental yellow fever virus infection in the Golden Hamster (Mesocricetus auratus) II. Pathology. J Infect Dis 183 10 (2001) 1437-1444
44. Rodrigues S.G., da Rosa A.P., Galler R., Barros V.L., Vieira Cde M., da Rosa J.F., et al. Yellow fever virus isolated from a fatal post vaccination event: an experimental comparative study with the 17DD vaccine strain in the Syrian hamster (Mesocricetus auratus). Rev Soc Bras Med Trop 37 Suppl 2 (2004) 69-74
45. Massad E., Coutinho F.A., Burattini M.N., Lopez L.F., and Struchiner C.J. Yellow fever vaccination: how much is enough?. Vaccine 23 30 (2005) 3908-3914